198 results on '"Campbell, Ross T."'
Search Results
2. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
3. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction
4. Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design
5. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
6. Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF
7. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
8. Reply: subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’
9. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies
10. Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes
11. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials
12. Reply to: Instrumental outcome modifiers to be considered among patients with acute heart failure
13. Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
14. Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials
15. Influenza vaccination: a simple, safe, and effective treatment for patients with ischaemic heart disease and heart failure
16. Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016
17. Defining Heart Failure Based on Imaging the Heart and Beyond
18. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
19. Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance?
20. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF
21. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies
22. Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials
23. Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction.
24. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction
25. Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials
26. Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion
27. Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort
28. Preventing Recurrent Cardioembolic Stroke: Right Approach, Right Patient (PRECISE) Study Protocol
29. Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)
30. Comorbidities and Differential Diagnosis in Heart Failure with Preserved Ejection Fraction
31. Preventing Recurrent Cardioembolic Stroke: Right Approach, Right Patient (PRECISE) Study Protocol.
32. Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion.
33. Influenza vaccination: Simple, safe, and effective for patients with ischaemic heart disease and heart failure.
34. Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction
35. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction
36. Elderly Woman Presenting After a Collapse
37. Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review
38. Acute heart failure: have we got it all wrong?
39. Urinary peptides in heart failure: a link to molecular pathophysiology
40. Sex differences in congestive markers in patients hospitalized for acute heart failure
41. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
42. Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling
43. A Randomized Trial Comparing The Effect Of Sacubitril/Valsartan To Valsartan On Left Ventricular Remodeling In Patients With Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction
44. The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure
45. Which patients with heart failure should receive specialist palliative care?
46. Redefining heart failure phenotypes based on ejection fraction
47. Talking to patients with heart failure about end of life
48. Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling.
49. Association is not causation: treatment effects cannot be estimated from observational data in heart failure
50. Reporting of lost to follow-up and treatment discontinuation in device and pharmacotherapy trials in chronic heart failure: a systematic review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.